Skip to content
Loading...

Liver Cancer Summit 2022

The scientific programme of the two-day Liver Cancer Summit 2022 provided delegates with a live experience dedicated entirely to primary liver cancers. International experts will deliver up-to-date talks on basic, translational, and clinical studies on hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA), and rare primary liver cancers.

The format combined state-of-the-art educational lectures and lively debates, with numerous occasions to interact with the experts. Because the boundaries are currently moving fast, global approaches were highlighted, whether this directly affects HCC and CCA in basic aspects, global epidemiology of liver tumours or treatment combination strategies.

Who should attend the summit

Liver Cancer Summit 2022 promises to bring together all of you engaged in tackling liver cancer, including:
  • clinicians and scientists, basic and clinical, from all fields related to liver cancer
  • investigators, physicians, surgeons, radiologists, biologists
  • nurses and allied health professionals
  • patient organisations
  • members of the biotech and pharmaceutical industries
We strongly encourage young clinicians and scientists to apply for the support we offer, such as waiving fees for the best accepted abstracts from Young Investigators. You are key to conquering liver cancer!

Reasons to attend the summit

See below the best reasons to attend the summit as highlighted by our faculty.

What can our delegates expect to take away from your presentation “The role of MAIT cells in liver cancers” at the Liver Cancer Summit 2022?

Check-point inhibition and novel adoptive immunotherapy approaches have revealed the inherent capacities of our immune system to target and eliminate established tumors. In this session, liver immunology in relation to liver physiology and liver cancers will be discussed.

Why should people attend the Liver Cancer Summit 2022?

Spanning from basic to clinical science this is the meeting of the year for anyone interested in liver cancer research.

What can our delegates expect to take away from your co-chaired session “Development of registries and cohort studies on liver cancer” at the Liver Cancer Summit 2022?

Design of registries and cohort studies is a key issue for advancing knowledge in specific populations with rare diseases or clinical profile not represented in clinical trials. In our session we will provide insight into the optimal strategy to implement such studies and avoid flawed assessment of what may be presented as real life.

Why should people attend the Liver Cancer Summit 2022?

The Summit brings together the most influential key opinion leaders who enjoy the debates around hot topics and burning research questions, while also exposing messages with limited evidence despite its transient visibility. Sharing time in such setting allows to understand where the field is moving to and become part of the community that paves the path to the future.

What can our delegates expect to take away from your co-chaired session “Untangling cirrhosis in liver cancer” at the Liver Cancer Summit 2022?

In the session the important interrelations between liver cancer and cirrhosis will be presented and discussed. In fact, there is controversy regarding the influence of the etiology of liver cirrhosis in the management of liver cancer. Also, it will be discussed the importance and need of evaluating portal hypertension and liver function prior to treatment, mostly if it is planned resection. These are all very practical issues that are of major importance in multidisciplinary teams, to decide the best options for each patient.

Why should people attend the Liver Cancer Summit 2022?

Liver cancer is presently a very frequent presentation of liver disease, as well a frequent complication of liver disease. Furthermore, recent years have witnessed major advances in the area. Consequently, most clinicians interested in liver disease need constant updates in the field. Also, it is an area of intense research, and during the Summit there will be plenty of symposium focused on research, as well as presentations. In addition, the format of the summit includes plenty of time for panel discussions, where you will have the opportunities to express your opinion or ask your questions.

What can our delegates expect to take away from your presentation “Overview on latest adjuvant and locoregional studies in liver cancer: focus on study design and lesson learned from CCA” at the Liver Cancer Summit 2022?

The design of clinical trials is always of paramount importance for their success. Design of study focusing on multidisciplinary approaches and non-pharmacological interventions poses unique challenges.

What can our delegates expect to take away from your  presentation “Modelling NASH HCC” at the Liver Cancer Summit 2022?

The presentation will summarize preclinical models of NASH to HCC transition and describe what we have learned so far for the translation and patient stratification. The panel discussion will emphasise on in vivo and in vitro models and evaluate the pros and cons of the latter.

What can our delegates expect to take away from your presentation “Challenges for translational research in liver cancer: basic research perspective” at the Liver Cancer Summit 2022?

Delegates attending this session will get a deeper insight into the strengths and disadvantages of the different animal models of liver cancer, the best ones to recapitulate the specific subtype of liver cancer, the most significant signaling pathways associated with them and the most efficient preclinical models in search of novel therapeutic avenues.

Why should people attend the Liver Cancer Summit 2022?

There are multiple reasons to attend the Liver Cancer Summit 2022. For both young researchers and established researchers it is a great opportunity to interact, present the latest results, meet with each other, get new ideas for the projects and start exciting collaborations.

What can our delegates expect to take away from your presentation “The role of mitochondrial oxidative metabolism in liver cancers” at the Liver Cancer Summit 2022?

Metabolism reprogramming is one of the cardinal hallmarks of tumors. Besides the well-known glycolytic tumor metabolism, more recently liver cancer cells were shown to utilize different nutritional sources through mitochondrial oxidative phosphorylation to survive in hostile microenvironments and support tumor cell growth.

Why should people attend the Liver Cancer Summit 2022?

This meeting represents a great opportunity to share the most important and recent findings from clinical to basic science in liver cancer. It also accelerates discussion and interaction among researchers and clinicians.

What can our delegates expect to take away from your co-chaired session “Design of clinical trials for adjuvant and locoregional strategies” at the Liver Cancer Summit 2022?

The session aims to provide an overview on the latest adjuvant and locoregional studies in liver cancer, focusing on clinical trial designs especially for CCA. We will discuss the rationale for combination therapies including systemic and locoregional approaches and we will delineate future concepts and strategies for primary liver cancer in different settings.

What can our delegates expect to take away from your co-chaired session “Latest data in systemic therapy for liver cancer” at the Liver Cancer Summit 2022?

This sessions aims to provide an overview on the latest developments in systemic therapies for primary liver cancer. We will discuss the relevance of precision oncological as well as immune-oncological approaches in HCC and CCA.
We will delineate future concepts and strategies for primary liver cancer

Why should people attend the Liver Cancer Summit 2022?

  • Discuss and exchange the latest developments in primary liver cancer with peers and experts from around the globe
  • Participate, network and support the mission to improve the outcome of primary liver cancer
  • Meet friends and colleagues

What can our delegates expect to take away from your presentation “Rationale for combination therapy” at the Liver Cancer Summit 2022?

To understand what are the reasons why combinations of a PD-1or PD-L1 inhibitor plus other drugs could improve patient outcomes in liver cancer and at what risk.

Why should people attend the Liver Cancer Summit 2022?

With important novelties in the field being reported over the last year, attending the Liver Cancer Summit 2022 is a great way to stay up-to-date and find new ideas for future research.

Liver Cancer Summit contest winner

Back To Top